Servier expands Tibsovo label with first combination OK in a rare form of AML
Just over a year after Servier shelled out nearly $2 billion to pick up Agios’ oncology portfolio — including the acute myeloid leukemia drug Tibsovo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
